Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fidia Spa ( (IT:FDA) ) just unveiled an update.
Fidia S.p.A. has reported improved financial results for the first half of 2025, with net revenues increasing by 38.2% compared to the previous year. Despite ongoing geopolitical uncertainties, the company is on track to achieve positive results for the first time in years, supported by a restructuring plan initiated in 2023. The company’s financial performance shows significant improvement, with a reduction in net losses and a positive EBT. Additionally, Fidia has entered into a new investment contract with Global Growth Holding Limited, which has led to an increase in the company’s share capital.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A. is a leading company in the field of numerical controls and the design, production, and marketing of high-performance integrated milling systems. It operates internationally and is listed on Euronext Milan of Borsa Italiana.
YTD Price Performance: -95.45%
Average Trading Volume: 424,199
Technical Sentiment Signal: Strong Sell
Current Market Cap: €1.57M
See more insights into FDA stock on TipRanks’ Stock Analysis page.